Showing papers on "Alveolar hydatid disease published in 1980"

Alveolar hydatid disease. A review of clinical features of 33 indigenous cases of Echinococcus multilocularis infection in Alaskan Eskimos.

Abstract: The clinical features of 33 cases of alveolar hydatid disease (AHD) in Alaskan Eskimos and a review of the surgical experience with this disease are presented. Among untreated patients, progression of the disease to a fatal outcome was observed in 70%. The primary hepatic lesion resembles cancer, and errors in diagnosis by both the surgeon and pathologist are common. Although surgical resection of the entire primary hepatic lesion offers the only proven curative treatment, only 26% of those explored were resectable. All seven patients resected for cure are alive 6-27 years post-operatively (average survival, 14.7 years). A 5-year experience with continuous mebendazole therapy in the management of five nonresectable cases of AHD indicates that a favorable effect of this drug is being observed. It now appears that Echinococcus infections are no longer the sole province of the surgeon. Although the role of medical therapy is not yet clearly defined, it must be considered in the management of all cases of AHD. The first reported locally-acquired case of AHD in the conterminous United States, and the widespread occurrence and expanding range of E. multilocularis in the north-central United States and south-central Canada, point to the increasing public health importance of alveolar hydatid disease.

Is alveolar hydatid disease of the liver incurable

Abstract: The etiologic agent of alveolar hydatid disease is Echinococcus multilocularis. Infestation of the liver by the larvae of this Cestode results in an infiltrative mass that behaves biologically very much like a malignant tumor. From 1955 to 1978, 13 patients with alveolar hydatid disease of the liver were investigated, operated and followed at the University Medical Center of Lausanne, Switzerland. Due to the extension of the lesions, six patients had exploratory laparotomy with biopsy only; the other seven were submitted to hepatic resection. Follow-up demonstrated that the disease progresses slowly and that a resection, even if incomplete, can afford long-lasting relief. However the present data suggest that surgical cure of alveolar hydatid disease must be very rare.

Alveolar hydatid disease of the liver with Budd-Chiari syndrome.

Abstract: Alveolar hydatid disease in man is the intermediate stage in the life cycle of the tapeworm Echinococcus multilocularis. This is a rare disease restricted to very few areas of the world. The occurrence of this disease in India is now described for (so far as the authors are aware) the first time. Some unusual features of the disease are highlighted in this patient. The hepatic lesion had infiltrated into the right atrial wall resembling an atrial tumour. The ostium of the inferior vena cava was occluded, causing Budd-Chiari syndrome. The radiological and haemodynamic study of the hepatic outflow tract in this disease are documented.

Chemotherapy of cestode infections

Abstract: The cestode infections are one of the most common intestinal parasitic diseases responsible for several health hazards in man and animals all over the world. Surprisingly, the chemotherapy of these parasites remained backward till the beginning of past decade which witnessed a considerable progress in this direction. Today, cestodiasis is considered as a major helminth problem both in advanced and developing countries which not only threat the health and general well being of humans but also hamper the economy of milk, meat and wool producing regions of the world. The incidence of cestode infections has always been alarming [1–3], however recently it has been estimated [4] that 80,000,000 people suffer from Taenia saginata and T. solium and there are 2,000,000 cases of Diphyllobothrium latum infection throughout the world.

9 cases of portal hypertension of rare etiology

Abstract: Nine cases of portal hypertension of unusual etiology are presented: 1 with retroperitoneal fibrosis, 2 with alveolar hydatid disease, 3 with arterio-portal fistula, 2 with primary biliary cirrhosis and 1 with sarcoidosis.